1. Home
  2. SNDX vs DRH Comparison

SNDX vs DRH Comparison

Compare SNDX & DRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$21.32

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

HOLD

Current Price

$10.03

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
DRH
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2016
2005

Fundamental Metrics

Financial Performance
Metric
SNDX
DRH
Price
$21.32
$10.03
Analyst Decision
Strong Buy
Buy
Analyst Count
13
9
Target Price
$80.23
$9.81
AVG Volume (30 Days)
1.2M
3.2M
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
3.36%
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$111,304,000.00
$1,125,008,000.00
Revenue This Year
$617.40
N/A
Revenue Next Year
$115.70
$2.30
P/E Ratio
N/A
$36.97
Revenue Growth
595.65
0.95
52 Week Low
$8.58
$6.19
52 Week High
$22.73
$9.83

Technical Indicators

Market Signals
Indicator
SNDX
DRH
Relative Strength Index (RSI) 55.53 65.85
Support Level $20.00 $9.39
Resistance Level $21.89 $9.73
Average True Range (ATR) 1.07 0.27
MACD 0.00 0.04
Stochastic Oscillator 68.62 100.00

Price Performance

Historical Comparison
SNDX
DRH

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.

Share on Social Networks: